A new imaging technique to detect recurrent prostate cancer is tested in new clinical trial

Microscope in front of digital background

A new imaging study for men who have already had either surgery or radiation for prostate cancer and have rising levels of prostate-specific antigen (PSA) is now open at the NIH Clinical Center. Rising PSA strongly indicates that prostate cancer has recurred and may have spread to other parts of the body. However, standard imaging techniques, including x-ray, ultrasound, MRI, CT and PET scan, cannot accurately locate sites of metastasis. 18F-DCFPyL PET/CT, a second-generation PET agent, uses radiolabeled small molecules that bind to specific receptors on cancer cells. The radioactive portion of these molecules acts like a beacon that can be detected by a positron emission tomography (PET) camera. The study, led by Peter Choyke, M.D., F.A.C.R., of the Molecular Imaging Program, aims to see if 18F-DCFPyL PET/CT will improve doctors’ ability to assess high-risk primary tumors, detect sites of recurrent prostate cancer and target therapies to specific sites of recurrence. For more information about this study, please visit: https://ccr.cancer.gov/molecular-imaging-program/peter-l-choyke.

To view all CCR clinical trials, visit: https://ccr.cancer.gov/clinical-trials
Subscribe to the latest CCR clinical trials news. 

Summary Posted: Sat, 07/01/2017